Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an announcement.
Hangzhou Tigermed Consulting Co., Ltd. reported that its first extraordinary general meeting of 2026 was duly convened in Hangzhou on March 5, with all seven directors in attendance either in person or via video. The meeting, chaired by board chairman Dr. Ye Xiaoping, was open to A-share holders who could vote in person, by proxy or online in accordance with PRC regulations.
The company announced that the special resolution put to shareholders at the meeting was passed by poll, with legal counsel Jia Yuan Law Offices confirming that the convening and voting procedures complied with PRC laws, securities rules, and the company’s articles of association. Of the 855,142,270 shares eligible to vote, holders of 431,255,969 shares, or about 50.43% of voting rights, participated, underscoring a legally valid process and demonstrating solid shareholder engagement across both A shares and H shares despite treasury shares being excluded from voting.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-based clinical research and pharmaceutical services provider listed in Hong Kong and Shenzhen. The company operates in the contract research organization (CRO) industry, supporting drug development and related services for biopharmaceutical clients in domestic and international markets.
Average Trading Volume: 2,190,587
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.82B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.